Location of Repository

Establishment of a C1sA targeted mouse line and the differential expression of the complement serine protease C1sA and the related gene C1sB in mouse tissues

By Meenu Jassal


The complement system bridges the innate and adaptive immune responses. Complement can be activated via three distinct pathways, the classical, lectin and alternative pathways, all of which play a crucial role in the identification and elimination of pathogenic microorganisms. The classical pathway (CP) is activated mainly by immune complexes (complexes of antigen and immunoglobulin). The lectin pathway (LP) is activated when a carbohydrate recognition complex and associated serine proteases bind to specific carbohydrate patterns on the surface of pathogens. In addition to providing protection from microbial infections, the LP has been shown to be involved in inducing post-ischemic inflammatory tissue loss (ischemia/ reperfusion injury), which significantly contributes to the pathology of ischemic diseases such as, myocardial, renal and GI ischemia. \ud Separate mouse models of CP and LP deficiency are available, mice deficient in C1q (the CP recognition complex) and MASP-2 (a serine protease essential for LP activation), respectively. However, a model of combined CP and LP deficiency is not available. It has not been possible to generate mice deficient of both C1q and MASP-2, because the genes are located on the same chromosome in close proximity, and mice deficient in C4 (a constituent of both pathways) are not genuinely LP deficient, because the LP can activate C3 in the absence of C4. To establish a mouse strain deficient of both pathways, the gene for murine C1s was targeted the essential serine protease of the CP, with the aim of producing a C1s/MASP-2 double deficient mouse. A C1s deficient line would also be a valuable model to study C1q functional activity in the absence of CP activation. The mouse has two genes for C1s, C1sA and C1sB. The expression profiles for C1sA and C1sB in normal mouse tissue were assessed using qRT-PCR and in situ hybridisation, and confirmed that C1sA is widely expressed whereas C1sB expression is restricted to the testis. Thus C1sB is very unlikely to compensate for C1sA in a C1sA deficient mouse line. C1sA was targeted and the germ line transmission of the disrupted allele was confirmed. However, intercrossing of heterozygote mice did not result in the expected generation of homozygous C1sA deficient mice. Analysis of the offspring indicated that homozygous deficiency for C1sA appears to be lethal

Publisher: University of Leicester
Year: 2010
OAI identifier: oai:lra.le.ac.uk:2381/7952

Suggested articles



  1. 1991.Oligomeric domain structure of human complement factor H by X-ray and neutron solution scattering.
  2. (2005). a g e occurrence of invasive infection, artherosclerosis, and rheumatic disease.
  3. (1984). A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity,
  4. (1978). Activation of the first component of human complement (C1) by antibody-antigen aggregates.
  5. (1988). Analysis of the interaction between properdin and factor B, components of the alternativepathway C3 convertase of complement.
  6. (1995). Analysis of the N-linked oligosaccharides of human C1s using electrospray ionisation mass spectrometry.
  7. Assignment of the complement serine protease genes C1r and C1s to chromosome 12 region 12p13.
  8. (1996). Autoantibodies to the collagen-like region of C1q are strongly associated with classical pathwaymediated hypocomplementemia in systemic lupus erythematosus.
  9. (1992). Baculovirus Expression Vectors:
  10. Baculovirus-mediated expression of truncated modular fragments from the catalytic region of human complement serine protease C1s.
  11. (2002). Biblography 248 |P a g e Arlaud,
  12. (1993). Biblography 249 |P a g e
  13. (2005). Biblography 252 |P a g e
  14. (2004). Biblography 253 |P a g e
  15. (1999). Biblography 256 |P a g e
  16. (1998). Biblography 258 |P a g e
  17. (1998). Biblography 261 |P a g e
  18. (2006). Biblography 262 |P a g e
  19. (1993). Biblography 264 |P a g e
  20. (2002). Biblography 265 |P a g e
  21. (1991). Biblography 266 |P a g e
  22. (2000). Biblography 267 |P a g e
  23. (1989). Biblography 268 |P a g e
  24. (2005). Biblography 269 |P a g e
  25. (1991). Biochemical characterization and tissue distribution of hamster complement C1s.
  26. Biosynthesis of the subcomponents C1q, C1r and C1s of the first component of complement (C1) by guinea pig hepatocyte primary cultures.
  27. (2006). Bypassing Complement: evolutionary lessons and future implications.
  28. (1998). C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.
  29. (1979). C1 inhibitordependent dissociation of human complement component C1 bound to immune complexes.
  30. (1998). C1q knock-out mice for the study of complement deficiency in autoimmune disease.
  31. (2000). C1q: structure, function and receptors.
  32. (2002). C1s, the protease messenger of C1. Structure, function and physiological significance.
  33. (1997). Complement and complement deficiencies.
  34. (1982). Complement biosynthesis by the human hepatoma-derived cell line HepG2.
  35. (2003). Complement C1r and C1s gene are duplicated in the mouse: differential expression generates alternative isomorphs in the liver and in the male reproductive system.
  36. (1989). Complement genes C1r and C1s feature an intronless serine protease domain closely related to haptoglobin.
  37. (1991). Complement lysis: a hole is a hole.
  38. (1999). Complement resistance of tumor cells: basal and induced mechanisms.
  39. (1986). Complement system proteins which interact with C3b and C4b. A superfamily of structurally related proteins.
  40. (1998). Complement-dependent clearance of apoptotic cells by human macrophages.
  41. (2001). Complement: first of two parts.
  42. (1998). Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H.
  43. (1987). Complete cDNA sequence of human complement C1s and close physical linkage of the homologous genes C1s and C1r.
  44. (1996). Control of the complement system.
  45. (2002). Crystal structure of the catalytic domain of human complement C1s: a serine protease with a handle.
  46. (2000). Cutting edge: complementactivating complex of ficolin and mannose-binding lectin-associated serine protease.
  47. (2006). Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections.
  48. (2003). Differential expression of the murine mannose-binding lectin A and C in lymphoid and non-lymphoid organs and tissue.
  49. (1999). Direct comparisin of GAPDH, β-Actin, Cyclophilin and 28S rRNA as internal standards for quantifying RNA levels under Hypoxia.
  50. (2002). Disorders of the Complement System: An Overview.
  51. (1999). Does properdin crosslink the cellular and the humoral immune response?
  52. (1993). Epidermal growth factor like modules.
  53. (2002). Expression and function of C1q receptors and C1q binding proteins at the cell surface.
  54. (1989). Expression of hemolytically active human complement component Chapter IX Biblography 254 |P a g e Clr proenzyme in insect cells using a baculovirus vector.
  55. (1997). Extrahepatic complement biosynthesis: where, when and why?
  56. (1994). Familial hemolytic-uremic syndrome and homozygous factor H deficiency.
  57. (2008). Ficolins: structure, function and associated diseases.
  58. (1990). Functional analysis of a 603 nucleotide open reading frame upstream of the polyhedrin gene of Autographa Californica nuclear polyhedrosis virus.
  59. (1983). g e complex-clearing mechanism.
  60. (1994). Hereditary C1q deficiency and systemic lupus erythematosus.
  61. (1996). High and low annealing temperatures increase both specificity and yield in touchdown and stepdown PCR.
  62. (1998). Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies.
  63. (1986). Human complement component C1s. Patial sequence determination of the heavy chain and identification of the peptide bond cleaved during activation.
  64. (2005). Human M-Ficolin is a secretory protein that activates the lectin complement pathway.
  65. (2005). Immunobiology- the immune system in health and disease. 6 th edition.
  66. (1998). In Vitro Stimulation of C1s Proteolytic Activities by C1s-Presenting Autoantibodies from Patients with Systemic Lupus Erythematosus.
  67. (1984). Inhibition of complement activation on the surface of cells after incorporation of decayaccelerating factor (DAF) into their membranes.
  68. (1991). Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b9.
  69. (2003). Innate immunity and brain inflammation: the key role of complement.
  70. (2000). Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein Map19.
  71. (2000). Interaction of mannose-binding protein with associated serine protease: effects of naturally occurring mutations.
  72. (1995). Interplay between promoter and Chapter IX Biblography 259 |P a g e structural gene variants control basal serum levels of mannan-binding protein.
  73. (2004). L-ficolin in children with recurrent respiratory infections.
  74. (2008). liters; add 484g of Tris, add 1l of
  75. (2006). Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2.
  76. (2006). Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation.
  77. (2005). Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation.
  78. (2003). Mannose-binding lectin deficiencies in infections and inflammatory disorders.
  79. (2004). Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. The New England
  80. (2005). Mannose-binding lectin: do we need it?
  81. (2003). Mannosebinding lectin deficiency-revisited.
  82. (1992). Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism.
  83. (2003). Modern complement analysis.
  84. (1999). Molecular basis of human complement C1s deficiency.
  85. (1989). Molecular cloning. A laboratory manual. 2 nd edition.
  86. (1999). Molecular defects in variant forms of mannose-binding protein associated with immunodeficiency.
  87. (2007). Molecular interaction between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway.
  88. (1988). Molecular organization and function of the complement system.
  89. (1989). Molecular structure and functional characterization of human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulphated glycoprotein 2, a constituent of rat testis fluid.
  90. (1992). Noval vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction.
  91. (1977). Nucleotide sequence and amplification in bacteria of structural gene for rat growth hormone.
  92. (2003). On the site of C4 deposition upon complement activation via the mannan-binding lectin pathway or the classical pathway.
  93. Phylogenetic perspectives in innate immunity.
  94. (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.
  95. (1997). Product differentiation by analysis of DNA melting curves during the polymerase chain reaction.
  96. (1983). Proteins involved in the activation and control of the two pathways of human complement.
  97. (1977). Rat insulin genes: construction of plasmids containing the coding sequences.
  98. (2007). Recognition of microorganisms and activation of the immune response. Nature ,
  99. (1992). Recombinant human complement subcomponent C1s lacking .beta.-hydroxyasparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex.
  100. (2002). Regulation of circulating immune complexes by complement receptor type 1 on erythrocytes in chronic viral liver diseases.
  101. (1992). Regulation of complement by membrane proteins: an overview.
  102. (1996). Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement.
  103. (2003). Role for the alternative complement pathway in ischemia/reperfusion injury.
  104. (2005). Role of Lficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci.
  105. (1998). Selective complement C1s deficiency caused by homozygous fourbase deletion in the C1s gene.
  106. (1993). Several vascular complement inhibitors are present on human sperm.
  107. (1998). Structural and functional studies on C1r and C1s: new insights into the mechanisms involved in C1 activity and assembly.
  108. (2001). Structural biology of C1: dissection of complex molecular machinery.
  109. Structural biology of C1.
  110. (1983). Studies on transformation of E. coli with plasmids.
  111. (1991). Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema.
  112. (1988). The binding site for C1q on IgG. Nature,
  113. (2006). The central role of the alternative complement pathway in human disease.
  114. (1985). The classical complement pathway: activation and regulation of the first complement component.
  115. (2006). The complement system in liver disease.
  116. (1998). The complement system in reproduction.
  117. (1997). The LightCycler: a microvolume multisample fluorimeter with rapid temperature control.
  118. (1996). The reaction mechanism of the internal thioester in the human complement component C4.
  119. (2003). The regulation of the complement system: insights from genetically-engineered mice.
  120. (1993). The role of complement component C3b and its receptors in sperm-oocyte interaction.
  121. (2003). The role of mannose-binding lectin in health and disease.
  122. (1998). Therapeutic inhibition of the complement system.
  123. (1991). Touchdown' PCR to circumvent spurious priming during gene amplification.
  124. (1999). Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene.
  125. (1998). Two lineages of mannose-binding lectin-associated serine protease (MASP) in vertebrates.
  126. (1994). β- amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q-A chain.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.